BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37474400)

  • 1. Transcriptomic Heterogeneity of Expansile Cribriform and Other Gleason Pattern 4 Prostate Cancer Subtypes.
    Chappidi MR; Sjöström M; Greenland NY; Cowan JE; Baskin AS; Shee K; Simko JP; Chan E; Stohr BA; Washington SL; Nguyen HG; Quigley DA; Davicioni E; Feng FY; Carroll PR; Cooperberg MR
    Eur Urol Oncol; 2024 Apr; 7(2):222-230. PubMed ID: 37474400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Significance of Percentage and Architectural Types of Contemporary Gleason Pattern 4 Prostate Cancer in Radical Prostatectomy.
    Choy B; Pearce SM; Anderson BB; Shalhav AL; Zagaja G; Eggener SE; Paner GP
    Am J Surg Pathol; 2016 Oct; 40(10):1400-6. PubMed ID: 27379821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
    Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
    Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expansile cribriform Gleason pattern 4 has histopathologic and molecular features of aggressiveness and greater risk of biochemical failure compared to glomerulation Gleason pattern 4.
    Greenland NY; Cowan JE; Zhang L; Carroll PR; Chan E; Stohr BA; Simko JP
    Prostate; 2020 May; 80(8):653-659. PubMed ID: 32220141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
    Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
    Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
    Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
    Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
    Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
    Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular risk classifier score and biochemical recurrence risk are associated with cribriform pattern type in Gleason 3+4=7 prostate cancer.
    Greenland NY; Cooperberg MR; Wong AC; Chan E; Carroll PR; Simko JP; Stohr BA
    Investig Clin Urol; 2022 Jan; 63(1):27-33. PubMed ID: 34983120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comedonecrosis Gleason pattern 5 is associated with worse clinical outcome in operated prostate cancer patients.
    Hansum T; Hollemans E; Verhoef EI; Bangma CH; Rietbergen J; Osanto S; Pelger RCM; van Wezel T; van der Poel H; Bekers E; Helleman J; Remmers S; van Leenders GJLH
    Mod Pathol; 2021 Nov; 34(11):2064-2070. PubMed ID: 34175896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer.
    Özsoy M; D'Andrea D; Moschini M; Foerster B; Abufaraj M; Mathieu R; Briganti A; Karakiewicz PI; Roupret M; Seitz C; Czech AK; Susani M; Shariat SF
    Urol Oncol; 2018 Apr; 36(4):158.e1-158.e6. PubMed ID: 29288003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy.
    Briganti A; Karnes RJ; Joniau S; Boorjian SA; Cozzarini C; Gandaglia G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Sun M; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T
    Eur Urol; 2014 Sep; 66(3):479-86. PubMed ID: 24345725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computationally Derived Cribriform Area Index from Prostate Cancer Hematoxylin and Eosin Images Is Associated with Biochemical Recurrence Following Radical Prostatectomy and Is Most Prognostic in Gleason Grade Group 2.
    Leo P; Chandramouli S; Farré X; Elliott R; Janowczyk A; Bera K; Fu P; Janaki N; El-Fahmawi A; Shahait M; Kim J; Lee D; Yamoah K; Rebbeck TR; Khani F; Robinson BD; Shih NNC; Feldman M; Gupta S; McKenney J; Lal P; Madabhushi A
    Eur Urol Focus; 2021 Jul; 7(4):722-732. PubMed ID: 33941504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer.
    Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
    Eur Urol; 2017 Jun; 71(6):907-912. PubMed ID: 27876305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphotropic Pattern of Prostate-specific Membrane Antigen-detected Metastases Among Biochemically Recurrent Radical Prostatectomy Patients with Cribriform Disease.
    Bernardino R; Sayyid RK; Al-Daqqaq Z; Tiwari R; Cockburn J; Vijayakanthan S; Qaoud Y; Berjaoui MB; Metser U; Berlin A; van der Kwast T; Fleshner NE
    Eur Urol Focus; 2023 Nov; 9(6):1016-1023. PubMed ID: 37268513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
    Jeyapala R; Savio AJ; Olkhov-Mitsel E; Kamdar S; Zhao F; Cuizon C; Liu RSC; Zlotta A; Fleshner N; van der Kwast T; Bapat B
    Eur Urol Oncol; 2019 May; 2(3):231-238. PubMed ID: 31200836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer.
    Masic S; Cowan JE; Washington SL; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
    Eur Urol Oncol; 2018 Oct; 1(5):386-394. PubMed ID: 31158077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptomic Features of Cribriform and Intraductal Carcinoma of the Prostate.
    Lone Z; Benidir T; Rainey M; Nair M; Davicioni E; Gibb EA; Williamson S; Gupta S; Chaim Ornstein M; Tendulkar R; Weight C; Nguyen JK; Klein EA; Mian OY
    Eur Urol Focus; 2022 Nov; 8(6):1575-1582. PubMed ID: 35662504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of intraductal carcinoma or cribriform in radical prostatectomy specimens of men opting for active surveillance: data from the PRIAS-JAPAN study.
    Tohi Y; Ishikawa R; Kato T; Miyakawa J; Matsumoto R; Mori K; Mitsuzuka K; Inokuchi J; Matsumura M; Shiga K; Naito H; Kohjimoto Y; Kawamura N; Inoue M; Kinoshita H; Hashimoto K; Goto K; Haba R; Kakehi Y; Sugimoto M
    Int J Clin Oncol; 2023 Feb; 28(2):299-305. PubMed ID: 36472710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.